FAP and neoplasm: Statistically significant antitumor activity was observed, with tumor growth inhibition rates of 111% and 113% (p < 0.05) in HEK-FAP tumor-bearing mice treated with 30 or 60 MBq of 177Lu-FAP-2286, respectively, compared to the vehicle-treated group, with no significant weight loss.